10.5281/zenodo.3264828
https://zenodo.org/records/3264828
oai:zenodo.org:3264828
Sandip S. Kshirsagar, Vaishali R. Shinde, Manjusha Nevase, Sayali Dudhal
Sandip S. Kshirsagar, Vaishali R. Shinde, Manjusha Nevase, Sayali Dudhal
Kasturi Shikshan Sanstha's College of Pharmacy, Shikrapur, Pune-412207, Maharashtra, India.
REVIEW ON BIOMARKERS: TOOL FOR DIAGNOSIS OF A DISEASE AND DRUG DEVELOPMENT
Zenodo
2019
Biomarker, Diagnostic Biomarkers, Surrogate Markers.
2019-06-30
10.5281/zenodo.3264827
https://zenodo.org/communities/iajpr
Creative Commons Attribution 4.0 International
Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. In this review we discuss the intrinsic properties of biological sample based efficacy measurements and how these relate to their implementation in oncology drug development by way of points to consider and examples. In short use of biomarker data will help us make the best possible use of precious human samples and maximize the chances of success of the most promising therapeutic approaches.